Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Mnemo raises $90 million series A to improve CAR T cells

by Megha Satyanarayana
June 18, 2021 | A version of this story appeared in Volume 99, Issue 23

 

Mnemo Therapeutics, a company specializing in cell therapy using chimeric antigen receptor T cells (CAR-Ts), has launched with $90 million in series A funding. Casdin Capital led the financing round. The funds will support development of Mnemo’s technology, which couples the ability to discover tumor-specific antigens with methods to improve CAR T cells’ memory and longevity. The Paris-based company was founded by Sebastian Amigorena of Institut Curie and Michel Sadelain of Memorial Sloan Kettering Cancer Center.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.